Biomarkers for personalized oncology: recent advances and future challenges

Kalia, Madhu

doi:10.1016/j.metabol.2014.10.027

Cited by 220 publications

(151 citation statements)

References 29 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…TKIs such as imatinib, dasatinib, and nilotinib have successfully improved the lifespan of patients with CML. [3] This compound improved the overall survival rates of CML patients to 90% over 5 years and 88% over 8 years. [2] Use of trastuzumab in breast cancer patients with her2-neu overexpression is another example of precision medicine.…”

Section: The Presence Of Precision Oncology Todaymentioning

confidence: 99%

Precision medicine in oncology – On a journey from dreams to reality

Patel

Shah

2018

Int J Mol Immuno Oncol.

View full text Add to dashboard Cite

Precision medicine is defined as treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from another patient with similar clinical presentation. Precision Oncology is an innovation at the cusp of blooming. We reviewed the status of precision oncology today, and discuss the flaws, mainly in next-generation sequencing (NGS) and the design of clinical trials thus far. Precision oncology although paints a glossy imagery, the reality is laden with inherent flaws, lack of guided research and a generalisability for the clinical market. The scenario in India is similar. It remains to be seen, if Precision Oncology is able to withstand the scrutiny likely to come its way, and if it can appeal largely to a complex socioeconomic market as India. We conclude that precision oncology is not far from an exponential boom, provided the right questions are asked, and answers derived.

show abstract

Section: The Presence Of Precision Oncology Todaymentioning

confidence: 99%

Precision medicine in oncology – On a journey from dreams to reality

Patel

Shah

2018

Int J Mol Immuno Oncol.

View full text Add to dashboard Cite

show abstract

“…46 Chen et al 47 successfully constructed the molecular imaging agent C225-USPIO, which is capable of targeting the EGFR of A549 lung cancer cells. C225-USPIO showed good targeting and specificity, leading to a significant reduction in the MRI T2 value.…”

Section: Using Spion In Cancer Imaging Applicationsmentioning

confidence: 99%

Superparamagnetic iron oxide nanoparticles for MR imaging of pancreatic cancer: Potential for early diagnosis through targeted strategies

Zhang¹,

Zou²,

Chen³

et al. 2015

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (SPION)-based magnetic resonance imaging is a powerful, noninvasive tool in biomedical imaging. The recent embedding of SPIO in nanoencapsulations that had different controllable surface properties has now made it possible to use SPIO in the imaging of metabolic processes. The two major issues to realize maximized and selective SPIO cancer targeting are the minimization of macrophage uptake and the preferential binding to cancerous cells over healthy neighbor cells. The utility of SPIO has been shown in clinical applications using a series of marketed SPION-based contrast agents. Applications have ranged from detecting inflammatory diseases to the specific identification of cell surface markers expressed on tumors. This review focuses on iron-oxide-based nanoparticles, to include the physiochemical properties of SPION surface engineering and its synthetic methods as well as SPIO imaging applications and specifically targeted SPIO conjugates (e.g. targeted probes) for labeling cancerous, cell-surface molecules. As a specific application of this technology, we discuss its use in the imaging of pancreatic duct adenocarcinoma in addition to its potential for use in early diagnosis through targeted strategies.

show abstract

“…This approach should increase drug efficacy and decrease toxicity, thus leading to a more personalized and improved cancer treatment. [5][6][7][8] Although FFPE-IHC has achieved worldwide acceptance and is used as a standard procedure in morphology-based sciences and pharmacological drug-related research, the exact molecular mechanism of this procedure is still not well understood. The quality, reproducibility and validity of immunostains depend substantially on 3 major factors: 1) tissue fixation and processing; 2) unmasking of epitopes, which is also termed antigen retrieval (AR); and 3) the affinity and specificity of the primary detection antibody to the relevant epitope.…”

Section: Introductionmentioning

confidence: 99%

Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule

Dobosz¹,

Haupt²,

Scheuer³

2016

mAbs

View full text Add to dashboard Cite

Preclinical efficacy studies of antibodies targeting a tumor-associated antigen are only justified when the expression of the relevant antigen has been demonstrated. Conventionally, antigen expression level is examined by immunohistochemistry of formalin-fixed paraffin-embedded tumor tissue section. This method represents the diagnostic "gold standard" for tumor target evaluation, but is affected by a number of factors, such as epitope masking and insufficient antigen retrieval. As a consequence, variances and discrepancies in histological staining results can occur, which may influence decision-making and therapeutic outcome. To overcome these problems, we have used different fluorescence-labeled therapeutic antibodies targeting human epidermal growth factor receptor (HER) family members and insulin-like growth factor-1 receptor (IGF1R) in combination with fluorescence imaging modalities to determine tumor antigen expression, drug-target interaction, and biodistribution and tumor saturation kinetics in non-small cell lung cancer xenografts. For this, whole-body fluorescence intensities of labeled antibodies, applied as a single compound or antibody mixture, were measured in Calu-1 and Calu-3 tumor-bearing mice, then ex vivo multispectral tumor tissue analysis at microscopic resolution was performed. With the aid of this simple and fast imaging method, we were able to analyze the tumor cell receptor status of HER1-3 and IGF1R, monitor the antibody-target interaction and evaluate the receptor binding sites of anti-HER2-targeting antibodies. Based on this, the most suitable tumor model, best therapeutic antibody, and optimal treatment dosage and application schedule was selected. Predictions drawn from obtained imaging data were in excellent concordance with outcome of conducted preclinical efficacy studies. Our results clearly demonstrate the great potential of combined in vivo and ex vivo fluorescence imaging for the preclinical development and characterization of monoclonal antibodies.

show abstract

Biomarkers for personalized oncology: recent advances and future challenges

Cited by 220 publications

References 29 publications

Precision medicine in oncology – On a journey from dreams to reality

Precision medicine in oncology – On a journey from dreams to reality

Superparamagnetic iron oxide nanoparticles for MR imaging of pancreatic cancer: Potential for early diagnosis through targeted strategies

Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule

Contact Info

Product

Resources

About